Macrophage-tumor Crosstalk: Role of TAMR Tyrosine Kinase Receptors and of Their Ligands

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2011 Nov 15

PMID 22076650

Citations 20

Authors

Thomas Schmidt

Isabel Ben-Batalla

Alexander Schultze

Sonja Loges

Affiliations

Soon will be listed here.

Abstract

Ample clinical and preclinical evidence indicates that macrophages interact with tumor cells as well as with virtually all populations of host cells present in the tumor microenvironment. This crosstalk can strongly promote malignancy, but also has in principle the potential to inhibit tumor growth. Thus, it is of the utmost importance to improve our understanding of the mechanisms driving the pro- and antimalignant behavior of tumor-associated macrophages (TAMs) in order to develop better anticancer therapies. In this review, we discuss the biological consequences of reciprocal interactions between TAMs, cancer cells, endothelial cells, fibroblasts and other leukocyte subfractions within tumors. It was recently elucidated that tumors specifically educate macrophages to secrete growth arrest-specific gene 6 (Gas6), the common ligand of the Tyro3, Axl, Mer receptor (TAMR) family. In turn, Gas6 fosters tumor growth by promoting cancer cell proliferation. Therefore, the Gas6-TAMR axis might represent a novel target for disrupting tumor-macrophage crosstalk. We summarize here what is known about TAMR and their ligands in (human) cancer biology. In order to shed more light on the role of macrophages in human cancer, we additionally provide an overview of what is currently known about the prognostic impact of TAMs in human cancer.

Citing Articles

AXL signaling in cancer: from molecular insights to targeted therapies.

Yadav M, Sharma A, Patne K, Tabasum S, Suryavanshi J, Rawat L Signal Transduct Target Ther. 2025; 10(1):37.

PMID: 39924521 PMC: 11808115. DOI: 10.1038/s41392-024-02121-7.

Role of tumor-associated macrophages in hepatocellular carcinoma: impact, mechanism, and therapy.

Zhang Y, Han G, Gu J, Chen Z, Wu J Front Immunol. 2024; 15:1429812.

PMID: 39170620 PMC: 11335564. DOI: 10.3389/fimmu.2024.1429812.

Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer.

Moreira R, da Silva M, de Melo Vasconcelos C, da Silva T, Cordeiro G, Mattos-Jr L J Cancer Res Clin Oncol. 2023; 149(19):17651-17661.

PMID: 37843557 DOI: 10.1007/s00432-023-05437-z.

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?.

Borea F, Franczak M, Garcia M, Perrino M, Cordua N, Smolenski R Int J Mol Sci. 2023; 24(11).

PMID: 37298116 PMC: 10253134. DOI: 10.3390/ijms24119165.

Exploiting the efficacy of Tyro3 and folate receptors to enhance the delivery of gold nanoparticles into colorectal cancer cells .

Patel N, Ghali L, Roitt I, Munoz L, Bayford R Nanoscale Adv. 2022; 3(18):5373-5386.

PMID: 36132641 PMC: 9419080. DOI: 10.1039/d1na00318f.

References

Gyorffy B, Lage H . A Web-based data warehouse on gene expression in human malignant melanoma. J Invest Dermatol. 2006; 127(2):394-9. DOI: 10.1038/sj.jid.5700543. View

Smiley S, Boyer S, Heeb M, Griffin J, Grusby M . Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. Proc Natl Acad Sci U S A. 1997; 94(21):11484-9. PMC: 23513. DOI: 10.1073/pnas.94.21.11484. View

Manfioletti G, Brancolini C, Avanzi G, Schneider C . The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol. 1993; 13(8):4976-85. PMC: 360142. DOI: 10.1128/mcb.13.8.4976-4985.1993. View

Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Ruegg C, Christofori G . Myeloid cells contribute to tumor lymphangiogenesis. PLoS One. 2009; 4(9):e7067. PMC: 2738969. DOI: 10.1371/journal.pone.0007067. View

Dai W, Pan H, Hassanain H, Gupta S, Murphy Jr M . Molecular cloning of a novel receptor tyrosine kinase, tif, highly expressed in human ovary and testis. Oncogene. 1994; 9(3):975-9. View

Ojalvo L, Whittaker C, Condeelis J, Pollard J . Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol. 2009; 184(2):702-12. PMC: 3226722. DOI: 10.4049/jimmunol.0902360. View

Jiang H, Harris M, Rothman P . IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000; 105(6 Pt 1):1063-70. DOI: 10.1067/mai.2000.107604. View

Deng L, Zhou J, Sellers R, Li J, Nguyen A, Wang Y . A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol. 2010; 176(2):952-67. PMC: 2808099. DOI: 10.2353/ajpath.2010.090622. View

Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D . Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A. 2009; 106(35):14978-83. PMC: 2736429. DOI: 10.1073/pnas.0809784106. View

10.

Tjwa M, Bellido-Martin L, Lin Y, Lutgens E, Plaisance S, Bono F . Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood. 2007; 111(8):4096-105. DOI: 10.1182/blood-2007-05-089565. View

11.

Moussai D, Mitsui H, Pettersen J, Pierson K, Shah K, Suarez-Farinas M . The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C. J Invest Dermatol. 2010; 131(1):229-36. DOI: 10.1038/jid.2010.266. View

12.

de Palma M, Venneri M, Galli R, Sergi Sergi L, Politi L, Sampaolesi M . Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8(3):211-26. DOI: 10.1016/j.ccr.2005.08.002. View

13.

Zhu P, Baek S, Bourk E, Ohgi K, Garcia-Bassets I, Sanjo H . Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell. 2006; 124(3):615-29. DOI: 10.1016/j.cell.2005.12.032. View

14.

Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L . IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118(3):285-96. DOI: 10.1016/j.cell.2004.07.013. View

15.

Zhu S, Wurdak H, Wang Y, Galkin A, Tao H, Li J . A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A. 2009; 106(40):17025-30. PMC: 2761329. DOI: 10.1073/pnas.0909292106. View

16.

Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A . Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011; 19(4):512-26. DOI: 10.1016/j.ccr.2011.02.005. View

17.

De Bock K, Cauwenberghs S, Carmeliet P . Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev. 2010; 21(1):73-9. DOI: 10.1016/j.gde.2010.10.008. View

18.

Ghosh A, Secreto C, Boysen J, Sassoon T, Shanafelt T, Mukhopadhyay D . The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2010; 117(6):1928-37. PMC: 3056640. DOI: 10.1182/blood-2010-09-305649. View

19.

Wang H, Chen S, Chen Y, Wang H, Wu H, Tang H . The role of Tyro 3 subfamily receptors in the regulation of hemostasis and megakaryocytopoiesis. Haematologica. 2007; 92(5):643-50. DOI: 10.3324/haematol.10939. View

20.

Jia R, Hanafusa H . The proto-oncogene of v-eyk (v-ryk) is a novel receptor-type protein tyrosine kinase with extracellular Ig/GN-III domains. J Biol Chem. 1994; 269(3):1839-44. View